Compare Novartis AG (NVS) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Short Term Corporate Bond ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard Short Term Corporate Bond ETF trades at $78.58. The key difference: Novartis AG pays a 3.17% dividend while Vanguard Short Term Corporate Bond ETF pays none, and Novartis AG is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VCSH | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Fixed Income |
52-Week High | $168.62 | $80.20 |
52-Week Low | $113.50 | $78.45 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
VCSH trades at $78.64, down 0.1% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a consistent dividend payout, with recent distributions of $0.29-$0.30 per share. News highlights institutional interest, such as Allspring Global Investments' 1.47 million share purchase in July 2026, while comparisons with peers like ISTB focus on yield and diversification.
The outlook remains cautious due to the bearish technical setup and potential interest rate volatility. Opportunities include the ETF's high yield and low expense ratio, but risks involve Fed policy uncertainty and competitive pressure from other short-term bond funds. Investor sentiment is mixed, balancing income appeal against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
